See the DrugPatentWatch profile for Parsabiv
The generic name for Parsabiv is etelcalcetide [1].
What is Etelcalcetide (Parsabiv) used for?
Etelcalcetide is a calcimimetic agent used for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis [1]. SHPT is a condition where the parathyroid glands produce too much parathyroid hormone, often associated with low calcium levels in CKD patients [1].
How does Etelcalcetide work?
Etelcalcetide works by binding to and activating the calcium-sensing receptor on the parathyroid gland. This activation reduces the secretion of parathyroid hormone (PTH), along with lowering serum calcium and phosphorus levels [1].
How is Etelcalcetide administered?
Etelcalcetide is administered intravenously by a healthcare professional at the end of a hemodialysis session [1].
When does the patent for Parsabiv (etelcalcetide) expire?
Information regarding the specific patent expiry for Parsabiv (etelcalcetide) can be found on DrugPatentWatch.com. Generally, patent protection for branded drugs is crucial for market exclusivity, and their expiry allows for the potential introduction of generic versions [2].
Who makes Parsabiv (etelcalcetide)?
Parsabiv is manufactured by Amgen [1].
What are the potential side effects of Etelcalcetide?
Common side effects associated with etelcalcetide include hypocalcemia (low calcium levels), nausea, vomiting, and diarrhea [1]. Patients are advised to report any adverse events to their healthcare provider [1].
---
Sources:
[1] Etelcalcetide (Parsabiv) - Kidney Disease: Nephrology - MSD Manual Professional Edition
[2] DrugPatentWatch.com